Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

Healthcare Biotechnology
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Satellos Bioscience Inc Com > Further Analysis
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by 75020780on Nov 22, 2017 7:49pm
130 Views
Post# 27015756

RE:RE:Further Analysis

RE:RE:Further AnalysisI bought this a while ago with the understanding that we would be getting a $33mil payment upon P3 from Immune... when I evaluated my purchase I thought:

hey.. P3 will start in 2018, cash burn is good until around the same time, there's risk in not starting a P3 due to P2 failure but that risk I feel is low..and I felt that the market would end up valuing this at cash or a little higher when the P3 news and payment come through.. which is approx 8x of today. 

Im not pumping.. just saying how I evaluated my purchase at $0.045 a few months ago.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities